CSL (ASX:CSL) said Tuesday CSL Seqirus was awarded a contract by the Health Emergency Preparedness and Response Authority to support the pandemic preparedness plans of 17 European Union and European Economic Area member states as well as the European Commission.

Under the contract, 27 million doses of pandemic influenza vaccine have been reserved with CSL Seqirus, which can be ordered by the participating countries in the event of an influenza pandemic, according to a statement.

The deal requires CSL Seqirus to be prepared to rapidly manufacture and deliver these vaccine doses. The doses will be produced at the company's manufacturing site in Liverpool, UK.